The emergence of genome-based drug repositioning

Science Translational Medicine

Volumn 3, Issue 96, 2011, Pages

  Lussier, Yves A ^a,b   Chen, James L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANDROGEN RECEPTOR; BCR ABL PROTEIN; ESTROGEN RECEPTOR; MESSENGER RNA; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; FRUCTOSE; TOPIRAMATE;

BINDING SITE; BIOINFORMATICS; BIOMEDICINE; DRUG REPOSITIONING; DRUG RESEARCH; ENTERITIS; GENE EXPRESSION; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; INFORMATION PROCESSING; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; NEOPLASM; NONHUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSLATIONAL RESEARCH; ANIMAL; BIOLOGY; DRUG DEVELOPMENT; METHODOLOGY; NOTE;

ANIMALS; ANTICONVULSANTS; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; DRUG REPOSITIONING; FRUCTOSE; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84867338005     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001512     Document Type: Review

References (25)

1. M H Van Regenmortel, Reductionism and complexity in molecular biology. Scientists now have the tools to unravel biological and overcome the limitations of reductionism. EMBO Rep. 5, 1016-1020 (2004).
2. M. Sirota, J T Dudley, J. Kim, A P Chiang, A A Morgan, A. Sweet-Cordero, J. Sage, A J Butte, Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 96, 96ra77 (2011).
3. M S Boguski, K D Mandl, V P Sukhatme, Repurposing with a diff erence. Science 324, 1394-1395 (2009).
4. J T Dudley, M. Sirota, M. Shenoy, R. Pai, S. Roedder, A P Chiang, A A Morgan, M. Sarwal, P J Pasricha, A J Butte, Computational repositioning of the anticonvulstant topiramate for infl ammatory bowel disease. Sci. Transl. Med. 96, 96ra76 (2011).
5. F. Crick, Central dogma of molecular biology. Nature 227, 561-563 (1970).
6. M S Blois, Information and Medicine: The Nature of Medical Descriptions (Univ. of California Press, Berkeley, 1984).
7. U. McDermott, J R Downing, M R Stratton, Genomics and the continuum of cancer care. N. Engl. J. Med. 364, 340-350 (2011).
8. T. Iwamoto, G. Bianchini, D. Booser, Y. Qi, C. Coutant, C Y Shiang, L. Santarpia, J. Matsuoka, G N Hortobagyi, W F Symmans, F A Holmes, J. O'Shaughnessy, B. Hellerstedt, J. Pippen, F. Andre, R. Simon, L. Pusztai, Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J. Natl. Cancer Inst. 103, 264-272 (2011).
9. J. Tsai, J T Lee, W. Wang, J. Zhang, H. Cho, S. Mamo, R. Bremer, S. Gillette, J. Kong, N K Haass, K. Sproesser, L. Li, K S Smalley, D. Fong, Y L Zhu, A. Marimuthu, H. Nguyen, B. Lam, J. Liu, I. Cheung, J. Rice, Y. Suzuki, C. Luu, C. Settachatgul, R. Shellooe, J. Cantwell, S H Kim, J. Schlessinger, K Y Zhang, B L West, B. Powell, G. Habets, C. Zhang, P N Ibrahim, P. Hirth, D R Artis, M. Herlyn, G. Bollag, Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. U.S.A. 105, 3041-3046 (2008).
10. H M Kantarjian, J. Cortes, S. O'Brien, F J Giles, M. Albitar, M B Rios, J. Shan, S. Faderl, G. Garcia-Manero, D A Thomas, D. Resta, M. Talpaz, Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99, 3547-3553 (2002).
11. E H Romond, E A Perez, J. Bryant, V J Suman, C E Geyer, Jr, N E Davidson, E. Tan-Chiu, S. Martino, S. Paik, P A Kaufman, S M Swain, T M Pisansky, L. Fehrenbacher, L A Kutteh, V G Vogel, D W Visscher, G. Yothers, R B Jenkins, A M Brown, S R Dakhil, E P Mamounas, W L Lingle, P M Klein, J N Ingle, N. Wolmark, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
12. R. Simon, Roadmap for developing and validating therapeutically relevant genomic classifi ers. J. Clin. Oncol. 23, 7332-7341 (2005).
13. E. Huang, S. Ishida, J. Pittman, H. Dressman, A. Bild, M. Kloos, M. D'Amico, R G Pestell, M. West, J R Nevins, Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat. Genet. 34, 226-230 (2003).
14. J R Nevins, A. Potti, Mining gene expression profi les: Expression signatures as cancer phenotypes. Nat. Rev. Genet. 8, 601-609 (2007).
15. A L Hopkins, Network pharmacology. Nat. Biotechnol. 25, 1110-1111 (2007).
16. A. Subramanian, P. Tamayo, V K Mootha, S. Mukherjee, B L Ebert, M A Gillette, A. Paulovich, S L Pomeroy, T R Golub, E S Lander, J P Mesirov, Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profi les. Proc. Natl. Acad. Sci. U.S.A. 102, 15545-15550 (2005).
17. V K Mootha, C M Lindgren, K F Eriksson, A. Subramanian, S. Sihag, J. Lehar, P. Puigserver, E. Carlsson, M. Ridderstråle, E. Laurila, N. Houstis, M J Daly, N. Patterson, J P Mesirov, T R Golub, P. Tamayo, B. Spiegelman, E S Lander, J N Hirschhorn, D. Altshuler, L C Groop, PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267-273 (2003).
18. K H Bleicher, H J Böhm, K. Müller, A I Alanine, Hit and lead generation: Beyond high-throughput screening. Nat. Rev. Drug Discov. 2, 369-378 (2003).
19. E E Schadt, S H Friend, D A Shaywitz, A network view of disease and compound screening. Nat. Rev. Drug Discov. 8, 286-295 (2009).
20. N T Hansen, S. Brunak, R B Altman, Generating genome-scale candidate gene lists for pharmacogenomics. Clin. Pharmacol. Ther. 86, 183-189 (2009).
21. A. Gottlieb, G Y Stein, E. Ruppin, R. Sharan, PREDICT: A method for inferring novel drug indications with application to personalized medicine. Mol. Syst. Biol. 7, 496 (2011).
22. T E Klein, R B Altman, N. Eriksson, B F Gage, S E Kimmel, M T Lee, N A Limdi, D. Page, D M Roden, M J Wagner, M D Caldwell, J A Johnson, International Warfarin Pharmacogenetics Consortium, Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
23. F. Iorio, R. Bosotti, E. Scacheri, V. Belcastro, P. Mithbaokar, R. Ferriero, L. Murino, R. Tagliaferri, N. Brunetti-Pierri, A. Isacchi, D. di Bernardo, Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl. Acad. Sci. U.S.A. 107, 14621-14626 (2010).
24. P. Mendiratta, E. Mostaghel, J. Guinney, A K Tewari, A. Porrello, W T Barry, P S Nelson, P G Febbo, Genomic strategy for targeting therapy in castration-resistant prostate cancer. J. Clin. Oncol. 27, 2022-2029 (2009).
25. Acknowledgments: We thank E. Rebman and K. Regan for their contribution to the revisions and the illustrations. Funding: This work was supported by NIH grants 5UL1RR024999, PAAR-U19GM061393-11, 5P30CA014599-35, and 3UL1RR024999-03S3. Competing interests: The authors declare no competing interests.